SCO 792

Drug Profile

SCO 792

Alternative Names: SCO-792; TAK-792

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer SCOHIA PHARMA; Takeda
  • Class Obesity therapies
  • Mechanism of Action Enteropeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetes mellitus; Diabetic nephropathies
  • No development reported Obesity

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Obesity(In volunteers) in Japan (PO)
  • 30 Jun 2018 Scohia Pharma completes a phase I trial in Diabetic nephropathies (In volunteers) in Japan (PO) (JapicCTI183826)
  • 26 Dec 2017 Phase-I clinical trials in Diabetes mellitus in Japan (PO) (Scohia Pharma pipeline-December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top